These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38394229)

  • 1. Combination treatment to improve mucociliary transport of Pseudomonas aeruginosa biofilms.
    Rouillard KR; Esther CP; Kissner WJ; Plott LM; Bowman DW; Markovetz MR; Hill DB
    PLoS One; 2024; 19(2):e0294120. PubMed ID: 38394229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination Treatment to Improve Mucociliary Transport of
    Rouillard KR; Esther CP; Kissner WJ; Plott LM; Bowman DW; Markovetz MR; Hill DB
    bioRxiv; 2023 Aug; ():. PubMed ID: 37645913
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Altering the viscoelastic properties of mucus-grown
    Rouillard KR; Markovetz MR; Kissner WJ; Boone WL; Plott LM; Hill DB
    Biofilm; 2023 Dec; 5():100104. PubMed ID: 36711323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Mucin and DNA Concentrations in Airway Mucus on Pseudomonas aeruginosa Biofilm Recalcitrance.
    Rouillard KR; Kissner WJ; Markovetz MR; Hill DB
    mSphere; 2022 Aug; 7(4):e0029122. PubMed ID: 35968965
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The DeltaF508-CFTR mutation results in increased biofilm formation by Pseudomonas aeruginosa by increasing iron availability.
    Moreau-Marquis S; Bomberger JM; Anderson GG; Swiatecka-Urban A; Ye S; O'Toole GA; Stanton BA
    Am J Physiol Lung Cell Mol Physiol; 2008 Jul; 295(1):L25-37. PubMed ID: 18359885
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PEGylation of Tobramycin Improves Mucus Penetration and Antimicrobial Activity against Pseudomonas aeruginosa Biofilms in Vitro.
    Bahamondez-Canas TF; Zhang H; Tewes F; Leal J; Smyth HDC
    Mol Pharm; 2018 Apr; 15(4):1643-1652. PubMed ID: 29514003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mucus polymer concentration and
    Greenwald MA; Meinig SL; Plott LM; Roca C; Higgs MG; Vitko NP; Markovetz MR; Rouillard KR; Carpenter J; Kesimer M; Hill DB; Schisler JC; Wolfgang MC
    mBio; 2024 Jun; 15(6):e0345123. PubMed ID: 38651896
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity.
    Agyeman AA; López-Causapé C; Rogers KE; Lucas DD; Cortés-Lara S; Gomis-Font MA; Fraile-Ribot P; Figuerola J; Lang Y; Franklyn ERT; Lee WL; Zhou J; Zhang Y; Bulitta JB; Boyce JD; Nation RL; Oliver A; Landersdorfer CB
    Int J Antimicrob Agents; 2023 Sep; 62(3):106887. PubMed ID: 37315906
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells.
    Yu Q; Griffin EF; Moreau-Marquis S; Schwartzman JD; Stanton BA; O'Toole GA
    J Antimicrob Chemother; 2012 Nov; 67(11):2673-81. PubMed ID: 22843834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effects of Antibiotic Combination Treatments on Pseudomonas aeruginosa Tolerance Evolution and Coexistence with Stenotrophomonas maltophilia.
    Law JP; Wood AJ; Friman VP
    Microbiol Spectr; 2022 Dec; 10(6):e0184222. PubMed ID: 36453898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
    Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
    J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of Calgary and Microfluidic BioFlux Systems To Test the Activity of Fosfomycin and Tobramycin Alone and in Combination against Cystic Fibrosis Pseudomonas aeruginosa Biofilms.
    Díez-Aguilar M; Morosini MI; Köksal E; Oliver A; Ekkelenkamp M; Cantón R
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29084746
    [No Abstract]   [Full Text] [Related]  

  • 13. Simulated Intravenous versus Inhaled Tobramycin with or without Intravenous Ceftazidime Evaluated against Hypermutable Pseudomonas aeruginosa via a Dynamic Biofilm Model and Mechanism-Based Modeling.
    Bilal H; Tait JR; Lang Y; Zhou J; Bergen PJ; Peleg AY; Bulitta JB; Oliver A; Nation RL; Landersdorfer CB
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0220321. PubMed ID: 35041509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells.
    Moreau-Marquis S; O'Toole GA; Stanton BA
    Am J Respir Cell Mol Biol; 2009 Sep; 41(3):305-13. PubMed ID: 19168700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic Activity of Repurposed Peptide Drug Glatiramer Acetate with Tobramycin against Cystic Fibrosis Pseudomonas aeruginosa.
    Murphy RA; Coates M; Thrane S; Sabnis A; Harrison J; Schelenz S; Edwards AM; Vorup-Jensen T; Davies JC
    Microbiol Spectr; 2022 Aug; 10(4):e0081322. PubMed ID: 35727066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pulmonary mucus surrogate for investigating antibiotic permeation and activity against Pseudomonas aeruginosa biofilms.
    Frisch S; Boese A; Huck B; Horstmann JC; Ho DK; Schwarzkopf K; Murgia X; Loretz B; de Souza Carvalho-Wodarz C; Lehr CM
    J Antimicrob Chemother; 2021 May; 76(6):1472-1479. PubMed ID: 33712824
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System of Biofilm Formation.
    Price KE; Orazi G; Ruoff KL; Hebert WP; O'Toole GA; Mastoridis P
    PLoS One; 2015; 10(10):e0141192. PubMed ID: 26506004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An Antipersister Strategy for Treatment of Chronic Pseudomonas aeruginosa Infections.
    Koeva M; Gutu AD; Hebert W; Wager JD; Yonker LM; O'Toole GA; Ausubel FM; Moskowitz SM; Joseph-McCarthy D
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28923873
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dispersal of Epithelium-Associated Pseudomonas aeruginosa Biofilms.
    Zemke AC; D'Amico EJ; Snell EC; Torres AM; Kasturiarachi N; Bomberger JM
    mSphere; 2020 Jul; 5(4):. PubMed ID: 32669459
    [No Abstract]   [Full Text] [Related]  

  • 20. The ionophore oxyclozanide enhances tobramycin killing of Pseudomonas aeruginosa biofilms by permeabilizing cells and depolarizing the membrane potential.
    Maiden MM; Zachos MP; Waters CM
    J Antimicrob Chemother; 2019 Apr; 74(4):894-906. PubMed ID: 30624737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.